New Two-Drug combo aims to rally immune system against tough prostate cancer
NCT ID NCT05445609
Summary
This study is testing whether combining two immunotherapy drugs, vidutolimod and nivolumab, can help the body's immune system find and kill prostate cancer cells that have spread. It is for men whose cancer has stopped responding to standard hormone therapy and chemotherapy. The main goals are to see if the treatment is safe and if it can shrink tumors or lower PSA levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.